We have shown that VEDT delays pancreatic cancer progression and improves the survival of genetically engineered mouse models of pancreatic oncogenesis (LSL-KRASG12D/PDX-1-Cre and LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre [KPC]) [16, 17]. Here, PDX1 is linked to pancreatic neoplasm.